Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Bogac Aybey"'
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundRobust immune cell gene expression signatures are central to the analysis of single cell studies. Nearly all known sets of immune cell signatures have been derived by making use of only single gene expression datasets. Utilizing the power o
Externí odkaz:
https://doaj.org/article/5e38414e699f43fc964e48caa1459418
Autor:
Magda Markowska, Tomasz Cąkała, BłaŻej Miasojedow, Bogac Aybey, Dilafruz Juraeva, Johanna Mazur, Edith Ross, Eike Staub, Ewa Szczurek
Publikováno v:
Genome Biology, Vol 23, Iss 1, Pp 1-35 (2022)
Abstract Copy number alterations constitute important phenomena in tumor evolution. Whole genome single-cell sequencing gives insight into copy number profiles of individual cells, but is highly noisy. Here, we propose CONET, a probabilistic model fo
Externí odkaz:
https://doaj.org/article/d20d77c71f2d4d37be5e8c021c7ba926
Autor:
Malte Simon, Sadaf S. Mughal, Peter Horak, Sebastian Uhrig, Jonas Buchloh, Bogac Aybey, Albrecht Stenzinger, Hanno Glimm, Stefan Fröhling, Benedikt Brors, Charles D. Imbusch
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
Abstract Background Soft-tissue sarcomas (STS) are a heterogeneous group of mesenchymal tumors for which response to immunotherapies is not well established. Therefore, it is important to risk-stratify and identify STS patients who will most likely b
Externí odkaz:
https://doaj.org/article/95d5e3905f64467eb28b20271478949f
Autor:
Malte Simon, Sadaf S. Mughal, Peter Horak, Sebastian Uhrig, Jonas Buchloh, Bogac Aybey, Albrecht Stenzinger, Hanno Glimm, Stefan Fröhling, Benedikt Brors, Charles D. Imbusch
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/d7c7b1e647bc491ebcae01e7bf9696e0
Autor:
Christoph E. Heilig, Andreas Laßmann, Sadaf S. Mughal, Andreas Mock, Sebastian Pirmann, Veronica Teleanu, Marcus Renner, Carolin Andresen, Bruno C. Köhler, Bogac Aybey, Sebastian Bauer, Jens T. Siveke, Rainer Hamacher, Gunnar Folprecht, Stephan Richter, Evelin Schröck, Christian H. Brandts, Marit Ahrens, Peter Hohenberger, Gerlinde Egerer, Thomas Kindler, Melanie Boerries, Anna L. Illert, Nikolas von Bubnoff, Leonidas Apostolidis, Philipp J. Jost, C. Benedikt Westphalen, Wilko Weichert, Ulrich Keilholz, Frederick Klauschen, Katja Beck, Ulrike Winter, Daniela Richter, Lino Möhrmann, Michael Bitzer, Klaus Schulze-Osthoff, Benedikt Brors, Gunhild Mechtersheimer, Simon Kreutzfeldt, Christoph Heining, Daniel B. Lipka, Albrecht Stenzinger, Richard F. Schlenk, Peter Horak, Hanno Glimm, Daniel Hübschmann, Stefan Fröhling
Publikováno v:
European journal of cancer (Oxford, England : 1990). 172
The multi-receptor tyrosine kinase inhibitor pazopanib is approved for the treatment of advanced soft-tissue sarcoma and has also shown activity in other sarcoma subtypes. However, its clinical efficacy is highly variable, and no reliable predictors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff6fda4c299b22f9a9c7fcbced79b8bc
https://pubmed.ncbi.nlm.nih.gov/35763870
https://pubmed.ncbi.nlm.nih.gov/35763870
Autor:
Sebastian Uhrig, Benedikt Brors, Charles D. Imbusch, Hanno Glimm, Peter Horak, Bogac Aybey, Malte Simon, Sadaf S. Mughal, Albrecht Stenzinger, Jonas Buchloh, Stefan Fröhling
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
Background Soft-tissue sarcomas (STS) are a heterogeneous group of mesenchymal tumors for which response to immunotherapies is not well established. Therefore, it is important to risk-stratify and identify STS patients who will most likely benefit fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dd72b8d2a3916f809c393c5a3c2f84c
http://europepmc.org/articles/PMC8117561
http://europepmc.org/articles/PMC8117561